These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26756636)

  • 1. Thyroid Hormone, Hormone Analogs, and Angiogenesis.
    Davis PJ; Sudha T; Lin HY; Mousa SA
    Compr Physiol; 2015 Dec; 6(1):353-62. PubMed ID: 26756636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid hormone and angiogenesis.
    Luidens MK; Mousa SA; Davis FB; Lin HY; Davis PJ
    Vascul Pharmacol; 2010; 52(3-4):142-5. PubMed ID: 19879961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and functions of the plasma membrane receptor for thyroid hormone analogues.
    Lin HY; Cody V; Davis FB; Hercbergs AA; Luidens MK; Mousa SA; Davis PJ
    Discov Med; 2011 Apr; 11(59):337-47. PubMed ID: 21524387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormone induced angiogenesis through the integrin αvβ3/protein kinase D/histone deacetylase 5 signaling pathway.
    Liu X; Zheng N; Shi YN; Yuan J; Li L
    J Mol Endocrinol; 2014 Jun; 52(3):245-54. PubMed ID: 24532656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac.
    Davis PJ; Glinsky GV; Lin HY; Leith JT; Hercbergs A; Tang HY; Ashur-Fabian O; Incerpi S; Mousa SA
    Front Endocrinol (Lausanne); 2014; 5():240. PubMed ID: 25628605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis.
    Davis PJ; Lin HY; Sudha T; Yalcin M; Tang HY; Hercbergs A; Leith JT; Luidens MK; Ashur-Fabian O; Incerpi S; Mousa SA
    Onco Targets Ther; 2014; 7():1619-24. PubMed ID: 25258542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface.
    Davis FB; Mousa SA; O'Connor L; Mohamed S; Lin HY; Cao HJ; Davis PJ
    Circ Res; 2004 Jun; 94(11):1500-6. PubMed ID: 15117822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nongenomic Actions of Thyroid Hormone: The Integrin Component.
    Davis PJ; Mousa SA; Lin HY
    Physiol Rev; 2021 Jan; 101(1):319-352. PubMed ID: 32584192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications.
    Davis PJ; Davis FB; Mousa SA; Luidens MK; Lin HY
    Annu Rev Pharmacol Toxicol; 2011; 51():99-115. PubMed ID: 20868274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrac as an anti-angiogenic agent in cancer.
    Schmohl KA; Nelson PJ; Spitzweg C
    Endocr Relat Cancer; 2019 Jun; 26(6):R287-R304. PubMed ID: 31063970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model.
    Mousa SA; Davis FB; Mohamed S; Davis PJ; Feng X
    Int Angiol; 2006 Dec; 25(4):407-13. PubMed ID: 17164749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor.
    Davis PJ; Davis FB; Lin HY; Mousa SA; Zhou M; Luidens MK
    Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1238-46. PubMed ID: 19755667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin.
    Mousa SA; O'Connor LJ; Bergh JJ; Davis FB; Scanlan TS; Davis PJ
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):356-60. PubMed ID: 16116342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Basis of Nongenomic Actions of Thyroid Hormone.
    Davis PJ; Leonard JL; Lin HY; Leinung M; Mousa SA
    Vitam Horm; 2018; 106():67-96. PubMed ID: 29407448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid hormone and P-glycoprotein in tumor cells.
    Davis PJ; Incerpi S; Lin HY; Tang HY; Sudha T; Mousa SA
    Biomed Res Int; 2015; 2015():168427. PubMed ID: 25866761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells.
    Davis PJ; Lin HY; Hercbergs A; Mousa SA
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32645835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-surface receptor for thyroid hormone and tumor cell proliferation.
    Davis PJ; Davis FB; Lin HY; Bergh JJ; Mousa S; Hercbergs A; Fenstermaker RA; Ciesielski MJ
    Expert Rev Endocrinol Metab; 2006 Nov; 1(6):753-761. PubMed ID: 30754150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of nongenomic actions of thyroid hormone.
    Davis PJ; Leonard JL; Davis FB
    Front Neuroendocrinol; 2008 May; 29(2):211-8. PubMed ID: 17983645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer.
    Rajabi M; Yalcin M; Mousa SA
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1223-1227. PubMed ID: 29519736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.